Prediction of key pharmacokinetic parameters in human

Abstract

Abstract: Volume of distribution, clearance, half of life and bioavailability are crucial pharmacokinetic parameters determining the extent and sustained time of drugs exposed in vivo. Thus, in the stage of drug discovery and development, it is of particular interest to estimate the pharmacokinetic parameters of drug candidates in human as early as possible to select the most promising compounds for further development. This paper reviews recent developments in prediction of human key pharmacokinetic parameters based upon preclinical animal pharmacokinetic data, absorption and metabolism data in vitro, physico-chemical property and in silico prediction.

Key words: Prediction, Pharmacokinetic parameters, In vitro-in vivo correlation

CLC Number:

R969.1

ZHU Jian-ping, SUN Jian-guo, PENG Ying, WANG Guang-ji. Prediction of key pharmacokinetic parameters in human[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(6): 699-709.

References

[1] Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)[J]. Br J Clin Pharmacol, 1988,25(3): 387-396.
[2] Ismail K, John L. Can the pharmaceutical industry reduce attrition rates? [J].Nat Rev Drug Discov, 2004,3(8): 711-715.
[3] Obach R, Baxter J. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data[J]. J Pharmacol Exp Ther,1997, 283(1): 46-57.
[4] Wajima T, Fukumura K, Yano Y, et al. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state[J]. J Pharm Pharmacol, 2003,55(7): 939-949.
[5] Clausen J, Bickel MH. Prediction of drug distribution in distribution dialysis and in vivo from binding to tissues and blood[J]. J Pharm Sci, 1993,82(4): 345-349.
[6] Loren MB, Jonathan R, Xuhai B, et al. Prediction of Vss from in vitro tissue-binding studies[J]. Drug Metab Dispos, 2010,38(1):115-121.
[7] Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs[J]. J Pharm Sci,2001,90(4):436-447.
[8] Poulin P, Theil FP. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery[J]. J Pharm Sci, 2000,89(1):16-35.
[9] Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution[J]. J Pharm Sci, 2002,91(1): 129-156.
[10] Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases[J]. J Pharm Sci,2005,94(6):1 259-1276.
[11] Rodgers T, Rowland M. Physiologically based pharmacokinetic modeling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions[J]. J Pharm Sci,2006,95(6):1238-1257.
[12] Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: Understanding the processes[J]. Pharm Res,2007,24(5):918-933.
[13] De BS, Sinha V, Luca A,et al. The prediction of drug metabolism, tissue distribution and bioavailability of 50 structurally diverse compounds in rat using mechanism-based ADME prediction tools[J]. Drug Metab Dispos, 2007, 35(4):649-659.
[14] Poulin P, Theil F. “Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods”[J].J Pharm Sci, 2009,98(12): 4941-4961.
[15] Hollosy F, Valko K, A Hersey, et al. Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning[J]. J Med Chem, 2006, 49(24):6958-6971.
[16] Lobell M, Sivarajah V. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values[J]. Mol Divers, 2003,7(1): 69-87.
[17] Ghafourian T, Barzegar M, Hakimha N,et al. Quantitative structure- pharmacokinetic relationship modelling: apparent volume of distribution[J]. J Pharm Pharmacol, 2004,56(3): 339-350.
[18] Gleeson MP, Waters NJ, Paine SW,et al. In silico human and rat vss quantitative structure-activity relationship models[J]. J Med Chem,2006,49(6): 1953-1963.
[19] Ghafourian T, Jalali MB, Dastmalchi S, et al. QSPR models for the prediction of apparent volume of distribution[J].Int J Pharm, 2006,319(1/2): 82-97.
[20] Lombardo F, Obach RS, DiCapua FM, et al. A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human[J]. J Med Chem, 2006,49(7): 2262-2267.
[21] Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans.Three different approaches[J]. Xenobiotica, 1996,26(9): 887-895.
[22] Tang H, Mayersohn M. On the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: further support for a proposed model based on plasma protein binding[J]. J Clin Pharmacol,2006,46(4):398-400.
[23] Tang H, Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling[J]. Drug Metab Dispos,2005,33(9):1297-1303.
[24] Tang H, Mayershon M.A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry[J]. J Pharm Sci, 2006,95(8):1 783-1799.
[25] Sinha VK, De Buck SS, Fenu LA,et al. Predicting oral clearance in humans: how close can we get with allometry? [J]. Clin Pharmacokinet,2008,47(1): 35-45.
[26] Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans: I. Clearance[J]. Drug Metab Dispos, 2004,32(6):603-611.
[27] Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans[J]. J Pharm Sci,2004,93(10):2522-2534.
[28] Tang H, Hussain A, Leal M,et al. Interspecies prediction of human drug clearance based on scaling data from one or two animal species[J].Drug Metab Dispos, 2007,35(10):1886-1 893.
[29] Hu TM, Chiu SJ. Prediction of human drug clearance using a single-species, fixed-exponent allometric approach[J]. J Med Sci,2009,29(6): 331-339.
[30] 张倩,王广基. 药物代谢清除率体外预测模型研究进展与问题分析[J]. 药学学报,2007, 42 (10) : 1023-1028.
[31] Hallifax D, Houston JB. Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems[J]. Curr Drug Metab,2009,10(3): 307-321.
[32] 汪音,杨劲. 基于体外模型数据模拟和预测人体内群体药代参数[J]. 中国临床药理学与治疗学,2008,13(5): 545-551.
[33] Masato C, Ishii Y, Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development[J]. AAPS J, 2009,11(2): 261-276.
[34] Ito K, Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches[J]. Pharm Res,2005,22(1):103-112.
[35] Mohutsky MA, Chien JY, Ring BJ, et al. Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations[J]. Pharm Res,2006,23(4): 654-662.
[36] RobertJ R, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes[J]. Drug Metab Dispos,2005,33(9):1304-1311.
[37] Shiran MR, Proctor NJ. Prediction of metabolic drug clearance in humans:In vitro-in vivo extrapolation vs allometric scaling[J]. Xenobiotica,2006,36(7):567-580.
[38] Lave TH, Dupin S, Schmitt C, et al. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs[J]. J Pharm Sci, 1997,86(5):584-590.
[39] Kiyomi I, Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches[J]. Pharm Res, 2005,22(1):102-112.
[40] Davies B, Morris T. Physiological parameters in laboratory animals and humans[J]. Pharm Res,1993,10(7):1093-1096.
[41] Mahmood I. Interspecies scaling of biliary excreted drugs:a comparison of several methods[J]. J Pharm Sci, 2005,94(4): 883-892.
[42] Takao W, Hiroyuki K, Kazuya M,et al. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans[J]. J Pharmacol Exp Ther, 2009,328(2): 652-662.
[43] Poirier A, Cascais AC, Funk C, et al. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data[J]. J Pharmacokinet Pharmacodyn, 2009,36(6):585-611.
[44] Abe K, Bridges AS, Brouwer KLR. Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-coA[J]. Drug Metab Dispos,2009,37(3):447-452.
[45] Shiyin Y. In vitro permeability across caco-2 cells can predict in vivo (small intestine) absorption in man-fact or myth[J]. Pharm Res,1997,14(6):763-766.
[46] Aristides D, Lida K, Nikoletta F. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models[J]. Expert Opin Drug Metab Toxicol, 2007,3(4): 491-505.
[47] Gertz M, Harrison A, Houston JB,et al. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data[J]. Drug Metab Dispos,2009,38(7):1147-1158.
[48] Mahmood I. Can absolute oral bioavailability in humans be predicted from animals? A comparison of allometry and different indirect methods[J]. Drug Metabol Drug Interact, 2000,16(2):143-155.
[49] Cheng KC, Cheng L, Annette S. Prediction of oral drug absorption in humans - from cultured cell lines and experimental animals[J]. Expert Opin Drug Metab Toxicol, 2008,4(5):581-590.
[50] Tiago LM, Carlos A. Montanari,et al. Hologram QSAR model for the prediction of human oral bioavailability[J]. Bioorgan Med Chem, 2007,15(24):7738-7745.
[51] Haruo I, Kiyomi I, Yoshiaki K,et al. Prediction of human bioavailability from human oral administration data and animal pharmacokinetic data without data from intravenous administration of drugs in humans[J]. Pharm Res,2009,26(8): 1881-1889.